Mesenkia Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 5

Mesenkia Therapeutics General Information

Description

Developer of a healthcare research platform designed to develop a new drug for glioblastoma. The company's platform focuses on prolonging progression-free survival for aggressive primary and recurrent glioblastoma by inhibiting the proliferation of tumor- and glioma stem cells and reducing their capacity to invade and spread by targeting two different mechanisms, enabling patients with an antibody treatment that both stimulates the body's immune system and slows tumor growth.

Contact Information

Website
www.mesenkia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Kyrkogårdsgatan 11
  • 753 10 Uppsala
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Kyrkogårdsgatan 11
  • 753 10 Uppsala
  • Sweden

Mesenkia Therapeutics Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mesenkia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 01-Jan-2026 Completed Generating Revenue
3. Accelerator/Incubator 15-Sep-2025 Completed Generating Revenue
2. Early Stage VC 03-Jun-2025 $580K $580K Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2023 Completed Startup
To view Mesenkia Therapeutics’s complete valuation and funding history, request access »

Mesenkia Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Mesenkia Therapeutics’s complete cap table history, request access »

Mesenkia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a healthcare research platform designed to develop a new drug for glioblastoma. The company's platform focu
Drug Discovery
Uppsala, Sweden
7 As of 2026

San Diego, CA
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mesenkia Therapeutics Competitors (9)

One of Mesenkia Therapeutics’s 9 competitors is BPS Bioscience, a Corporation company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BPS Bioscience Corporation San Diego, CA
Gilead Formerly VC-backed Foster City, CA
AllCells Private Equity-Backed Alameda, CA
Bristol-Myers Squibb Corporation Princeton, NJ
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 9 competitors. Get the full list »

Mesenkia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mesenkia Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Nordic Mentor Network For Entrepreneurship Accelerator/Incubator
Uppsala Innovation Centre Accelerator/Incubator
Almi Invest Venture Capital Minority
UU Invest Venture Capital Minority
1stRound Accelerator/Incubator
To view Mesenkia Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Mesenkia Therapeutics FAQs

  • When was Mesenkia Therapeutics founded?

    Mesenkia Therapeutics was founded in 2023.

  • Where is Mesenkia Therapeutics headquartered?

    Mesenkia Therapeutics is headquartered in Uppsala, Sweden.

  • What is the size of Mesenkia Therapeutics?

    Mesenkia Therapeutics has 7 total employees.

  • What industry is Mesenkia Therapeutics in?

    Mesenkia Therapeutics’s primary industry is Drug Discovery.

  • Is Mesenkia Therapeutics a private or public company?

    Mesenkia Therapeutics is a Private company.

  • What is Mesenkia Therapeutics’s current revenue?

    The current revenue for Mesenkia Therapeutics is .

  • How much funding has Mesenkia Therapeutics raised over time?

    Mesenkia Therapeutics has raised $580K.

  • Who are Mesenkia Therapeutics’s investors?

    Nordic Mentor Network For Entrepreneurship, Uppsala Innovation Centre, Almi Invest, UU Invest, and 1stRound have invested in Mesenkia Therapeutics.

  • Who are Mesenkia Therapeutics’s competitors?

    BPS Bioscience, Gilead, AllCells, Bristol-Myers Squibb, and Merck & Co. are some of the 9 competitors of Mesenkia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process